Alphyn Biologics Raises $25M Series B to Advance Zabalafin Hydrogel Through Phase IIb Trials for Atopic Dermatitis
Key Insights
Alphyn Biologics (search) completed a $25 million Series B funding round led by QCA Investment Group (search) to support global Phase IIb trials of Zabalafin Hydrogel for atopic dermatitis (search) treatment.
The company will initiate a second Phase II clinical program for molluscum contagiosum virus (search), targeting what could become the first direct antiviral drug for this pediatric condition.
Zabalafin Hydrogel represents a multi-target therapeutic approach, directly addressing inflammation, itch, bacterial involvement, and dry skin components of atopic dermatitis (search) simultaneously.
Alphyn Biologics (search) has secured $25 million in Series B financing to advance its lead dermatology candidate Zabalafin Hydrogel through global Phase IIb trials for atopic dermatitis (search), marking a significant milestone for the clinical-stage company's multi-target therapeutic platform.
The twice-oversubscribed funding round, led by QCA Investment Group (search) with participation from existing and new investors, will support the global Phase IIb trial of Zabalafin Hydrogel for atopic dermatitis (search) (AD), the most common form of eczema (search). The proceeds will also enable initiation of a second Phase II clinical program for molluscum contagiosum virus (search) (MCV) and expand drug raw material supply capabilities.
Multi-Target Therapeutic Approach
Zabalafin Hydrogel distinguishes itself through its ability to simultaneously target the interconnected drivers of atopic dermatitis (search), including itch, inflammation, dry skin, and bacterial components. For AD treatment, the hydrogel directly addresses the immuno-inflammatory component of the disease, pruritus (itch), bacterial involvement, and xerosis (dry skin) in a single therapeutic approach.
The drug candidate is also being investigated for molluscum contagiosum virus (search), where it targets the virus itself while addressing associated inflammation, itch, dermatitis (molluscum rash), and bacterial infection complications. According to Alphyn, Zabalafin Hydrogel could become the first direct antiviral drug that is both effective and safe for MCV, offering a new treatment option specifically for pediatric patients affected by this highly contagious skin infection.
Clinical Development Strategy
"We are incredibly grateful for the support of our current and new investors," said Neal Koller, CEO of Alphyn Biologics (search). "This financing reflects their confidence in our multi-target therapeutic drug platform and our unique and highly differentiated drug candidates for atopic dermatitis (search) and the molluscum contagiosum virus (search)."
The company expects Zabalafin Hydrogel to provide sustained management and long-term control of both conditions through its multi-mechanism approach. Koller noted that the funding positions Alphyn to "rapidly advance Zabalafin Hydrogel towards our next key milestones - two pivotal Phase III trials - while broadening our pipeline of breakthrough therapies for skin diseases."
Company Background and Platform
Alphyn Biologics (search) operates as a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics based on its Zabalafin Platform. The platform incorporates multiple bioactive compounds with multiple mechanisms of action, designed to treat individual diseases through various pathways for improved efficacy while maintaining advantages in safety, tolerability, and regulatory positioning.
The US-based company, which became operational in 2020, maintains subsidiaries in Austria and Australia. With this Series B round, Alphyn has raised approximately $34 million in total funding, providing the financial foundation to advance its dermatology pipeline toward pivotal clinical trials and potential regulatory submissions.